Filing Flows › Companies › Ligand Pharmaceuticals › Report card
Ligand Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate4 of 5 reports beat the EPS estimate
Ligand Pharmaceuticals (LGND) beat the analysts' EPS estimate in 4 of its last 5 reports (80%), by +24.4% on average.
Beat rate80% of 5
Average surprise+24.4%
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q3 2026 | Oct 29, 2026 | $2.33 | $2.67 | +14.7% | $78.7M |
| Q2 2026 | Aug 6, 2026 | $1.95 | $2.37 | +21.5% | $63.7M |
| Q1 2026 | May 7, 2026 | $1.80 | $1.63 | -9.6% | $51.7M |
| Q4 2025 | Feb 26, 2026 | $1.50 | $2.02 | +34.9% | $59.7M |
| Q3 2025 | Nov 6, 2025 | $1.93 | $3.09 | +60.5% | $115M |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Ligand Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.